Social cognition assessment in progressive supranuclear palsy: The cognitive interface with frontotemporal dementia
Objective: To explore the cognitive profile of PSP patients in tests of social cognition and to compare their performance to patients with behavioural variant frontotemporal…Relationship of MDS-UPDRS non-motor symptoms to cognitive functioning in patients with Parkinson’s disease
Objective: To evaluate the relationship among individual items from the MDS-UPDRS Part I and measures of cognitive functioning in patients with PD. Background: Non-motor symptoms…Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III
Objective: To compare the utility for detecting Mild Cognitive Impairment in Parkinson's disease (PD-MCI) of three abbreviated global scales: the Montreal Cognitive Assessment (MoCA), the…Neuropsychological assessment in a cohort of patients with Parkinson’s disease
Objective: To evaluate the cognitive profile in a cohort of patients with Parkinson's disease (PD) using a standardised battery. Background: Cognitive impairment is a great…Accuracy of clinical diagnosis of dementia with Lewy bodies: A systematic review and meta-analysis
Objective: To perform a systematic review of the studies on diagnostic accuracy in dementia with Lewy bodies (DLB) and to meta-analyse sensitivity, specificity and accuracy…Prevalence of depression and dementia in Parkinson’s disease
Objective: The aim of this study was to estimate the prevalence of depressive and dementia symptoms in PD patients. Background: Parkinson's disease (PD) is a…Neuron specific protein S100B and cognitive impairment in various forms parkinsonism
Objective: In Parkinson's disease (PD) in almost all patients at the early stages of developing cognitive impairment. Background: Study of the degree of cognitive impairment,…Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
Objective: To evaluate the clinician response to Parkinson patients who developed behavioral side effects from dopamine agonists. Background: Side effects from dopamine agonists can be…Synaptic biomarkers for cognitive decline in Lewy body dementias and Alzheimer’s disease. A mass spectrometry approach
Objective: The aim of our study is to understand the role of synaptic dysfunction in cognitive decline by comparing the whole proteome of Parkinson's disease…Decline in drawing ability associated with frontal dysfunction after subthalamic nucleus deep brain stimulation in Parkinson’s disease
Objective: The aim of the present study was to elucidate the properties of drawing ability in Parkinson's disease (PD) patients after bilateral subthalamic nucleus deep…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.